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Introduction: Chronic rhinosinusitis (CRS) is highly prevalent, affecting 11% of the population. 21 
Studies evaluating the socio-economic impact of CRS are mostly limited to the US population. 22 
Currently there is no study that has evaluated the socio-economic costs of CRS in the UK. 23 
 24 
Methods: A case-control study of patients with CRS and healthy controls was conducted to 25 
investigate the wider socio-economic impact of the disease. Data on demographic and 26 
socioeconomic characteristics, out-of-pocket expenditure (OOPE), health resource utilisation, 27 
productivity losses and health-related quality of life (HRQoL) via the EQ-5D and SNOT-22 28 
instruments, were collected from questionnaires.   29 
 30 
Results: A total of 139 CRS participants and 67 control participants completed the 31 
questionnaires. The average total OOPE per patient extrapolated to a 12-month period was 32 
£304.84. Other important findings include significantly higher reported primary care 33 
interactions (4.14 vs. 1.16, p<0.001) as well as secondary care interactions (2.61 vs 0.4, 34 
p<0.001) in CRS group as compared to controls. The average total missed workdays was 35 
estimated to be 18.7 per patient per year. The estimated incremental healthcare cost of CRS 36 
per year is £ 16.8 billion or £2.8 billion per million inhabitants. Factors predictive of a higher 37 
OOPE include higher household occupancy and income and these accounted for only 9.7% of 38 
the total variance in total OOPEs. Other socioeconomic, demographic and HRQoL variables 39 
were not found to be predictive factors of OOPE. 40 
 41 
Conclusions: This study showed that CRS has a significant wider economic burden beyond the 42 
immediate direct healthcare costs. CRS participants had a high level of healthcare service use, 43 
OOPE and productivity loss. Results from this study will add to the existing limited data both 44 
for the UK and abroad and emphasises the need for effective treatments for these patients 45 
to reduce the disease impact. 46 
 47 




Chronic rhinosinusitis (CRS) affects about 11% of the population1 and whilst the impact of the 50 
disease is felt in both primary and secondary care, this has not yet translated to it receiving 51 
the same attention as other chronic diseases for research and funding. CRS is one of the most 52 
common conditions seen by ENT surgeons as well as by GPs accounting for approximately 53 
15% of ENT outpatient consultations. Primarily a medical disease, much of CRS is managed by 54 
GPs with those cases failing medical therapy in the community being referred to secondary 55 
care2. Recent evidence suggests that compliance with medical treatment and the factors 56 
related to that may also add to the burden of CRS management3-5, with the financial impact 57 
identified as a key theme by CRS patients6. 58 
   “Sinusitis” was cited as one of the top-10 most costly physical health conditions to American 59 
businesses7, as it has an increasing incidence in middle age and a subsequent socio-economic 60 
impact both to healthcare systems and to economies.  The evidence there is suggests the 61 
main burden of care in terms of cost falls on the individual (or the family)8-10, but is derived 62 
from an American model of health care and may not accurately reflect the UK National Health 63 
Service (NHS) picture. There are no published estimates of cost of health care and productivity 64 
losses for patients with CRS in the UK.  Recent findings from the USA estimate that patients 65 
with CRS spend more than $500 per year on health care and missed an average of 5.67 66 
workdays per year versus 3.74 days per year for patients without CRS10. This suggests a 67 
significant disease burden on both the health care system and on individuals that is equal to 68 
or exceeds diseases that are thought to be more serious. An earlier study by Bhattacharyya 69 
found that the overall economic cost was $1539 per patient8.  Ray et al estimated health care 70 
expenditures attributable to CRS and common co-morbidities were $5.78 billion in 199611 but 71 
did not look at out-of-pocket expenditures or time off work for patients. Also, in the USA, 72 
Anand concluded that the costs associated with CRS are higher due to increased clinic visits 73 
and prescriptions, as well as significant productivity losses12.  Surgical treatment for CRS may 74 
influence drug costs13, but this will depend on the level of intervention. UK Hospital Episode 75 
Statistics data suggest that approximately 20000 sinus operations are performed each year in 76 
England and Wales with a cost of £28 million per year but with 50% of these cases potentially 77 
being revision surgeries, there is clearly a long-term burden borne in secondary care6. In 78 
addition, the outpatient and primary care consultations combined are likely to represent a 79 




To identify the wider socio-economic costs of CRS to bring about a better understanding of 82 
the impact of the disease both to the patient and to the NHS.  83 
Methods 84 
The study was sponsored by the University of East Anglia (UEA) and funded by the Anthony 85 
Long and Bernice Bibby Trusts. Ethical approval was granted by the North of Scotland 86 
Research Ethics Committee (Ref: 13/NS/0045).  87 
Study Design 88 
The study was conducted as a prospective case-control study. It was opened to recruitment 89 
in the East of England in 2013 for a duration of 24 months. Three sites participated including 90 
James Paget University Hospital (JPUH), The Ipswich Hospital and the University of East Anglia. 91 
Participants were provided with an information leaflet that was also available through patient 92 
support group, Fifth Sense (www.fifthsense.org.uk) and the research group website 93 
(www.uea.ac.uk/rhinology-group). Participants were given the choice to receive paper 94 
questionnaire or electronic questionnaires by email.  Questionnaire responses were 95 
anonymous with no identification information (name, address/postcode, e-mail or 96 
telephone).  The information leaflet outlined that consent of study participation would be 97 
implied on completion of the anonymised questionnaire.  The questionnaires were returned 98 
by post in freepost envelopes, scanned into a secure UEA database electronically and further 99 
checked for missing data.    100 
 101 
Participants and Data Sources 102 
CRS Participants 103 
Inclusion Criteria 104 
Criteria for diagnosis of CRS with or without polyps (EPOS guidelines)14 105 
At least two symptoms must be present for at least 12 weeks and include: 106 
 One of either nasal blockage/obstruction/congestion and/or nasal discharge 107 
(anterior/posterior nasal drip) 108 
 and either facial pain/pressure and/or reduction or loss of sense of smell and additionally: 109 
 endoscopic signs of: polyps and/or mucopurulent discharge primarily from middle meatus 110 
and/or; oedema/mucosal obstruction primarily in middle meatus 111 
 and/or CT changes: mucosal changes within the ostiomeatal complex and/or sinuses 112 
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Patients were then classified as having chronic rhinosinusitis without polyps (CRSsNPs), 113 
chronic rhinosinusitis with nasal polyps (CRSwNPs) or allergic fungal rhinosinusitis (AFRS); 114 
patients with the latter additionally adhered to either the Bent and Kuhn criteria or the 115 
modified Vancouver criteria15. 116 
 117 
Healthy Control Participants  118 
Exclusion Criteria 119 
 Prior history of recurrent acute or chronic rhinosinusitis other than having had previous 120 
common colds (acute viral rhinosinusitis). 121 
 Any other nose/sinus disorders e.g allergic rhinitis  122 
 Active medical problems that have required a hospital visit within the last 12 months. 123 
Exclusion Criteria for Both Groups 124 
 Patients/controls unable to comprehend written English. 125 
 Patients/controls under the age of 18 years. 126 
 127 
Variables and data sources 128 
There were no published questionnaires to assess the socioeconomic impact of CRS but a 129 
validated questionnaire by Fox et al16  measuring the socioeconomic costs of food allergies 130 
was adapted17  and the final study questionnaire was further developed based on literature 131 
review, expert input and focus groups (Norfolk Public and Patient Involvement in Research)18, 132 
to allow comparison of data between the CRS group and control group. The questionnaire 133 
comprised of two parts; the first part captured information including demographic and 134 
socioeconomic information including household occupancy, occupation, highest academic 135 
qualification, type of work and work environment (manual/non-manual, outdoor/indoor), 136 
and annual household income. The second part of the questionnaire collected information on 137 
out-of-pocket expenditure, healthcare service use, missed workdays, as well as an assessment 138 
of quality of life and general well-being via the validated 5-level Euroqol 5-Dimension (EQ-5D-139 
5L)19 preference-based scales and the 22-item Sino-Nasal Outcome Test (SNOT-22)20.  An EQ-140 
5D index of 1.0 corresponds to full health, whilst the EQ-5D visual analogue scale health score 141 
rates perceived health state ranging from 0 (‘worst’ imaginable health) to 100 (‘best’ health 142 
state). The SNOT-22 allows a measure of sinonasal symptom severity, commonly used for CRS 143 
patients. This follows a Likert-scale response of 0 to 5 where 0 is ‘No problem’ and 5 is 144 
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‘problem as bad as it could be’ with total score ranging from 0 to 110. Higher total scores 145 
reflect worse symptom severity as well as daily functioning. 146 
Costing methodology 147 
Calculation of socioeconomic costs of CRS from a societal perspective was derived from a 148 
prevalence-based cost-of-illness method. This takes into account the direct (healthcare 149 
services costs and out-of-pocket expenditure) and indirect costs (productivity loss) within a 150 
given year. Monetary values are calculated in British pound sterling (GBP, £). All economic 151 
values were computed using 2014 figures which were the most appropriately available figures 152 
as the data were collected from 2013-2015.  The final estimate of total socioeconomic cost of 153 
CRS were derived by extrapolating the three-monthly direct and indirect costs to the entire 154 
year.  155 
 156 
Out-of-pocket expenditure (OOPE) 157 
The total out-of-pocket expenditure (OOPE) costs were calculated as the sum of direct 158 
medical and non-medical OOPE over three months. We considered three months to be an 159 
appropriate recall period. Participants were asked to recall the amount of OOPE incurred from 160 
medication and equipment use over five domains: painkillers, cold and flu remedies, nasal 161 
sprays, other medication, and health devices or equipment. Additional medical out-of-pocket 162 
spending includes private and alternative healthcare costs. Non-medical OOPE included travel 163 
expenses for primary and secondary care appointments. CRS participants were asked to state 164 
method of travel (walk or cycle, hospital or community transport, car, or public transport/taxi) 165 
as well as total distance travelled, transport charges and car park cost.  The total cost of 166 
private car travel is calculated by totaling the fuel cost and car park charges per clinic visit. 167 
The fuel cost per trip is estimated based on the official fuel cost per mile for 2014 of 13.57 168 
pence using the Automobile Association (AA)21 motoring cost. This cost per trip is then applied 169 
to the total number of encounters to primary and/or secondary healthcare appointments.  170 
 171 
Health care service use 172 
Information on healthcare service use assisted in the calculation of direct medical costs of 173 
CRS. Participants were asked to recall their service use both at primary care and secondary 174 
care levels. Primary care utilisation includes the number of consultations with GP and GP 175 
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practice nurses for both CRS and other reasons. Secondary care utilisation comprises of 176 
number of hospital visits; including outpatient and day-care appointments as well as inpatient 177 
hospital stay within the previous three months for both CRS and other reasons. The economic 178 
monetary estimate for direct medical cost was derived by multiplying healthcare utilisation 179 
with the respective unit costs. Unit costs were obtained from the year 2013/14 as outlined in 180 
national resources such as Personal Social Services Research Unit22 and NHS Reference Costs23  181 
(See Appendix 2). For certain unit costs that were not available, similar national resources 182 
particularly from the previous year were used to complete the gaps in the data.  183 
 184 
Productivity loss 185 
Indirect costs were obtained by measuring productivity loss due to absenteeism and 186 
household productivity loss. Productivity loss related to presenteeism was not considered in 187 
this study due to the challenges in measuring reduced productivity whilst at work via a 188 
patient-reported questionnaire.  A reduction in productivity is much less tangible than 189 
absence.  190 
Absenteeism was measured using the question “In the last 3 months, around how many days 191 
have you been off work?” with responses distinguishing CRS to non-CRS reasons. The 192 
monetary cost of productivity loss due to absenteeism was derived using the human capital 193 
approach method24 where production potential is based on average national earnings data. 194 
It is determined by multiplying the mean missed workdays per person by the average daily 195 
wage, based on the Annual Survey of Hours and Earnings; available on Office for National 196 
Statistics (See Appendix 2).   In order to extrapolate annual cost burden, it was assumed that 197 
the average productivity level within the last three months was consistent over the course of 198 
the year.   199 
Household productivity loss was calculated by asking patients who were not in employment 200 
(such as housewives and the retired group) the number of days they were unable to perform 201 
normal activities due to CRS in the last three months. These figures help to estimate the 202 
opportunity costs which is the potential income that could be earned by unpaid workers if 203 
they were to take up paid employment. Household productivity loss is reported separately 204 
from paid missed workdays due to the different costing valuation. This was calculated by 205 
assuming it was equal to the hourly wage of a housekeeper. Using the Annual Survey of Hours 206 




Statistical Methods  209 
Data collected were tabulated and analysed using SPSS Statistics for Macintosh version 23 210 
(SPSS, Chicago, IL).  Descriptive statistics were used to summarise the demographic, 211 
socioeconomic and quality of life variables. Due to the skewed cost data and non-normal 212 
distribution of total OOPE, the results were reported additionally using medians and 213 
interquartile range. Despite the non-normal distribution of cost data, standard non-214 
parametric methods and analyses of costs or use of log transformations are generally 215 
inappropriate because they are not focused on arithmetic means. Therefore, parametric 216 
methods of comparing arithmetic means such as the t-test was used as it tends to be fairly 217 
robust to non-normality25. All comparisons were reported at the p=0.05 level of significance. 218 
ANOVA test were used to compare variables with more than 2 groups. Univariate analyses 219 
were used to test the possible associations between the key independent variables and total 220 
OOPE. These variables include demographics, socioeconomic as well as health-related quality 221 
of life score. A multivariate regression analysis was then performed to model the mean OOPE 222 
as a linear function of the independent variables. All potential variables with a p-value lower 223 
than 0.10 were selected for multiple regression analysis. The results of the multiple regression 224 
are presented in 𝛽 values with associated p-values, and R2. Variables that were significant in 225 
the multiple model at p<0.05 were considered predictive of total OOPE. 226 
Results 227 
Study Participants 228 
From a total of 437 dispatched questionnaires, 212 questionnaires were returned (49% 229 
response rate); this was reduced to a final cohort of 206 after checking for duplicates and 230 
significant missing information. The cohort of 206 participants had an age range of 18 to 80 231 
(see flowchart (figure 1) for details). 232 
 233 
Descriptive and Outcome Data 234 
The 206 participants comprised of 139 CRS participants and 67 control participants; 52.5% 235 
males and 47.5% females in the CRS group and 67.3% female and 32.7% male in the control 236 
group. CRS diagnosis were sub-categorised into 33.8% with CRSsNP, 58.3% with CRSwNP and 237 
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7.9% with AFRS. Demographic and socioeconomic participant characteristics are summarized 238 
in Table 2. The mean age for the CRS subjects was 58 years old ranging from 26 to 80 years 239 
old. The mean age in the control group was 41 years old ranging from 18-68 years old. The 240 
majority of participants were of white-British background and born in the UK (90-93%) 241 
reflecting the demographic of East Anglia. In terms of employment, 59% of CRS subjects and 242 
71.7% of control subjects were employed either full time, part-time, or self-employed and 243 
31% of participants had annual household income between £20, 000 - 40, 000. The majority 244 
(91.5%) of participants relied on public healthcare alone whilst 8.5% had additional private 245 
healthcare coverage. Just over half (51.8%) of CRS patients and 28.4% of control group were 246 
exempted from prescription charges.  247 
 248 
Out-of-Pocket Expenditure (OOPE) 249 
The total OOPE including direct medical and non-medical costs incurred from CRS 250 
management over a 3-month period are outlined in Table 3.  The mean over-the-counter 251 
medication and health devices incurred by the CRS patient totalled to £30.54 (median £17.00, 252 
IQR £33.40) over the course of 3 months, which is significantly higher when compared to 253 
£5.74 (median £1.00, IQR £5.50) in adults without CRS (p<0.001). In summary, it was found 254 
that CRS subjects spend 5.3-fold greater than controls on over-the-counter medication. The 255 
mean total overall OOPE incurred over a 3-month period was significantly higher in CRS group 256 
at GBP £76.21 (median £44.23, IQR £71.18) in comparison to £12.68 (median £2.40, IQR 257 
£7.89) in adults without CRS (p<0.001).  The total average OOPE per CRS patient is therefore 258 
estimated to be £304.84 per annum. Table 3 shows further breakdown of OOPE comparing 259 
CRSsNP group and CRSwNP. The t-test did not display any significant differences in direct 260 
medical OOPE, direct non-medical OOPE and total OOPE within these two main CRS 261 
phenotypes. 262 
 263 
Healthcare resource utilisation 264 
Table 4 summarises the use and costs of healthcare services; primary care and secondary care 265 
within a three-month duration. CRS subjects had significantly higher total number of primary 266 
care visits than the control group (4.14 vs. 1.16, p<0.001). This amounted to an average 267 
primary care visit cost per patient of £130.13 (median £92.00, IQR £115.00) in the CRS group 268 
compared to the control group at £40.84. This difference may be largely accounted by the 269 
additional visits incurred by CRS-related problems. On the utilisation of secondary care 270 
 
 10 
services, CRS subjects recorded a higher outpatient interaction (2.61 vs 0.40, p<0.001) with 271 
an average total cost of £613.58 (median £166.00, IQR £512.00), as compared to £97.40 in 272 
the control group. Therefore, the mean number of secondary care visits and costs were 273 
approximately 6.3-fold greater for CRS patients when compared to the control group. This is 274 
largely due to the significantly higher outpatient visits and day-care visits by CRS participants 275 
for both CRS-related and non-CRS related reasons. The overall cost of both primary and 276 
secondary cost over 3 months amounted to £743.72 (median £286.00, IQR £673.00) for adult 277 
with CRS which were significantly higher than adults without CRS at £138.85 (median £41.70, 278 
IQR £59.70) p<0.001.  279 
 280 
Productivity loss 281 
The average number of workdays missed by employed participants due to CRS and non-CRS 282 
symptoms or treatments and its associated costs are outlined in Table 5. The mean workdays 283 
missed due to CRS reasons over a three-month period was 1.96 days (7.84 days per year). The 284 
mean total workdays missed accounting for CRS and non-CRS reasons over three months and 285 
its cost were found to be significantly higher for the CRS subject when compared to controls 286 
(4.68 vs 0.73, £566.07 vs. £88.14, p=0.007). On extrapolation, the average total workdays 287 
missed was estimated to be 18.7 days per patient per year. Within the CRS subtypes, there 288 
were no significant differences displayed in absenteeism between CRSsNP and CRSwNP.  In 289 
terms of household productivity costs, adults with CRS who are not in employment spend a 290 
mean of 0.95 days (£45.47) over 3 months where they were unable to perform normal 291 
function. There were no significant differences displayed in total household productivity loss 292 
in adults with CRS and without CRS (p=0.825). A breakdown of absenteeism in number of days 293 
in CRS participants is presented in Table 8.  294 
 295 
Societal cost and burden of CRS 296 
The overall average three-monthly costs, which accounted for OOPE, primary and secondary 297 
care costs and productivity loss, are outlined in Table 9. When calculating the total 298 
socioeconomic cost of CRS, all aspects of direct and indirect medical care needs to be 299 
included. To calculate the annual healthcare cost per individual, the three-month costs were 300 
extrapolated by multiplying by four with an assumption that it was consistent over the course 301 
of the year. The estimated average total cost per individual patient is outlined in Table 10 and 302 
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further illustrated in Figure 2. Adults with CRS incur a total healthcare cost of £4844.88 per 303 
annum with an incremental difference of £3782.44 when compared to adults without CRS. 304 
Healthcare service costs are the primary driver of total CRS expenditures (Figure 3). This may 305 
be due to multiple outpatient visits due to difficulty symptom control. Based on a national 306 
prevalence of CRS of 11%, and a population of approximately 40 million in 2014, the total 307 
overall healthcare cost of a CRS patient including CRS and non-CRS related reasons, has been 308 
calculated to be approximately £21 billion in 2014.  The estimated incremental increase of 309 
healthcare expenditure due to CRS is £16.8 billion per year in the UK based on 2014 estimates.  310 
(See Appendix 2). 311 
 312 
Health Related-Quality of Life (HRQoL) 313 
HRQoL of CRS patients were found to be below public average indicating a lower quality of 314 
life in CRS patients. Significant differences were displayed in mean scores between adults with 315 
CRS and control for SNOT-22, EQ-5D Index and VAS Health score. The average score for total 316 
SNOT-22 was 35.04 in the CRS group versus 5.64 in the control group (p<0.001). The mean 317 
EQ-5D index score for CRS patients were 0.77 which was significantly lower than the control 318 
group 0.936 (<0.001). The EQ-5D visual analogue health score was 72.81 in the CRS group and 319 
89.85 in the control group. A further detailed breakdown of quality of life measures between 320 
the CRS subtypes is also reported in Table 10. Interestingly, CRSwNP reported better QoL than 321 
those with CRSsNP with statistically significant differences displayed in SNOT-22, p=0.040 and 322 
EQ-5D Index, p=0.017.  323 
 324 
Associations of demographic and socioeconomic variables 325 
The result of the initial univariate analysis assessed associations between total OOPE with 326 
demographic, socioeconomic and health related quality of life variables (Table 7). Higher total 327 
OOPE were associated with higher number of household occupancy, employment status, and 328 
higher annual income (p<0.05). Stepwise multivariate linear regression showed that number 329 
of household occupancy (β=0.252) and income (β=0.221) independently predicted higher 330 
total OOPE over the last three-month period. Even though statistically significant at p-value 331 
<0.05 level, the strength of the relationship is considered weak. The final regression model 332 
only accounted for 9.6 percent of the total variance in the total OOPE over three months. 333 
Other socioeconomic, demographic and HRQoL variables were not found to be predictive 334 
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factors of OOPE. A separate analysis on over-the-counter (OTC) medication costs was 335 
performed to assess associations with HRQoL variables. There was a significant correlation 336 
between OTC medication costs with higher symptom severity via the total SNOT-22 score 337 
(0.278, p=0.001). Over-the-counter medication costs were inversely related to QoL, with the 338 
correlation between the Health score and OTC medication costs being -2.57 (p=0.002) and 339 
EQ5D Index score of -0.215 (p=0.011). 340 
Discussion 341 
Key Results 342 
When compared to studies of other chronic diseases socioeconomic data related to CRS is 343 
sparse and until now has lacked a comprehensive study in the UK. This study represents the 344 
first UK attempt to quantify the cost (OOPE) associated with CRS treatment particularly from 345 
an individual patient perspective. The total OOPE incurred per CRS patient is estimated to be 346 
£304.84 annually, in a publicly funded healthcare system. This study has demonstrated that 347 
CRS subjects incur a personal spend of 5.3-fold greater on OTC medication than the general 348 
population.  This significant personal monetary burden can be contributed to by a number of 349 
factors that include: the chronic nature of CRS, frequent exacerbations of symptoms 350 
necessitating visits to primary and secondary healthcare services and incomplete symptom 351 
control leading to higher use of additional therapies and over-the-counter medication26. With 352 
respect to direct costs and health care utilization, adults with CRS attended an average of 353 
approximately 3 additional primary care visits and approximately 2 additional secondary care 354 
visits, over a three-month period when compared to controls.   355 
Indirect costs take into account absenteeism (missed workdays), presenteeism (decreased 356 
productivity), as well as household productivity loss. In this study however, presenteeism was 357 
not evaluated due to the difficulty of estimating decreased productivity via a questionnaire-358 
based study. It was found that the mean absenteeism rate over three months for CRS patients 359 
and controls were 4.68 and 0.73 respectively. On extrapolation, the estimated average of 360 
missed workdays was 18.7 per CRS patient per year.  361 
 362 
Limitations 363 
One of the limitations of this study is that the control group consisted of a higher proportion 364 
of female and younger participants when compared to CRS group, although this may be 365 
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attributed to the missing information on age and gender for 18 control participants. 366 
Moreover, there is a selection bias given that the CRS participants were recruited in secondary 367 
care only, where patients typically reflect the more severe cases and therefore, contributing 368 
to a group where direct and indirect costs may be much higher. Thus, results from this study 369 
may not be wholly generalizable to the wider UK population with CRS. An important 370 
component that was not included in the analysis is medication prescription costs that 371 
originated from primary or secondary care. Given the available data, a future analysis can be 372 
undertaken to calculate costs based on British National Formulary and NHS prescription fees. 373 
It should also be noted that the current data represent a combination of patient reported 374 
expenditures as well as derived costs from unit cost estimates applied to utilization measures.  375 
Additionally, the OOPE data displayed skewed distribution; due to a small number of patients 376 
who utilize large amounts of resources and by a high number of patients with zero or very 377 
small cost values. The most appropriate statistical approach for cost analysis is debated in 378 
existing literature, where some have argued that the median could be more representative 379 
than the mean as a measure of central tendency whilst others argue that the arithmetic mean 380 
should be used in healthcare cost analysis as it directly informs decision makers27. Therefore, 381 
it is worth noting that mean costs reported in this study may not be the typical costs for any 382 
individual participant. The extrapolation of a three-month health care cost to an annualized 383 
health care cost can also over or underestimate the true cost of the disease.  384 
   The indirect cost from productivity loss is an underestimate, as presenteeism costs were not 385 
factored together. This is largely due to the difficulty on estimating reduced productivity 386 
assumptions via a self-reported questionnaire. Another aspect that was that was not included 387 
in analysis were indirect costs of missed workdays due to informal care from caregiver and 388 
childcare costs in relation to CRS healthcare appointments. Despite these items being 389 
included in the questionnaire, most participants did not record any information related to 390 
these and when present, there were no recorded costs associated.  Consequently, it can be 391 
assumed that the figures estimated in this study for direct and indirect cost due to CRS is 392 
potentially an under-estimate of the true monetary burden of CRS. 393 
Interpretation 394 
The previous research concerning the socioeconomic burden of CRS is limited with most 395 
studies carried out by the same principal investigator, Bhattacharya. In contrast, 396 
Bhattacharyya reported an annual average of 4.8 days missed workdays per CRS patient8. A 397 
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Canadian study by Yip et al.28 estimated an average of 20.6 workdays missed per year whilst 398 
Rudmik et al. reported an average of 24.6 days per year for patients with refractory CRS29 . 399 
Our findings may therefore be an estimate reflecting both refractory CRS and those with less 400 
severe phenotypes of CRS. Direct costs of disease are often subject to extrinsic factors such 401 
as economic cycles, legislative changes and health care utilisation30. On the other hand, 402 
indirect costs are associated with disease-specific QOL impairments. Our study showed that 403 
the average SNOT-22, EQ-5D index score, and health score of adults with CRS were lower than 404 
that in the general population. Higher OTC medication costs were associated with lower levels 405 
of health-related QOL. Thus, patient-borne cost can be minimised through effective, patient-406 
centred treatments. 407 
When looking at the burden to the society, a key finding of this study suggest that CRS has a 408 
considerable economic impact on the UK and the NHS, with an estimated incremental cost of 409 
£3782.44 attributable to CRS per individual per year. This figure includes healthcare costs, 410 
OOPE and productivity loss due to absenteeism as well as household productivity costs. An 411 
incremental estimate of £16.8 billion of healthcare cost was therefore attributed to CRS in 412 
2014.  This compares to an estimated €961.1 per individual/year for allergic rhinitis in a 413 
Swedish study 31. In contrast, for CRS, Bhattacharyya32 evaluated the US-based MEPS 414 
database in 2007 and reported an incremental direct healthcare expenditures estimate of 415 
$8.6 billion per year. However, it is worth noting that this figure did not include costs related 416 
to productivity loss and it was based on a lower CRS prevalence of approximately 5% (11.1 ± 417 
0.48 million adult patients in the US).  418 
Our results illustrate the distribution of CRS costs and their impact on patient, national 419 
healthcare system as well as to the employer. A key strength to this study is the use of a 420 
bottom-up approach to costing. Another strength to this study is the recall duration of three 421 
months, compared to other studies that is conducted over a 12-month recall period. 422 
Recording of expenditure are self-reported and thus patients may be subject to recall bias if 423 
the recall period is longer. It has been reported in studies on productivity loss that the 424 
accuracy of recall of missed workdays reduces to 51% at 1 year33. Future studies may include 425 
a further follow-up questionnaire after three to six months to allow a more accurate 426 
estimation of healthcare costs. A current programme of research underway also plans to 427 
establish the cost effectiveness and cost utility of medical and surgical treatment for CRS over 428 




It is worth to note that the sample population in our study comprised of a high proportion of 431 
white-British (93%) which is not entirely representative of people with CRS in the UK 432 
population, as according to the 2011 Census, White British ethnic group made up 433 
approximately 80.5% of the UK population35. Apart from that, a large proportion of the CRS 434 
group comprised of participants in retirement (36%) and thus may underestimate the total 435 
health care cost, given that residents aged 65 years and over, represented approximately 18% 436 
of the total UK population (2016)36. Despite the limitations of this cost-of-illness analysis, the 437 
findings from this study provides an insight to the financial impact of CRS that is vital in 438 
program planning and public policy design. This study is the first representative costing 439 
exercise on the socioeconomic burden of CRS in the UK to date, with particular attention to 440 
characterising the out-of-pocket expenditure borne by the individual patient. Suggested areas 441 
for future studies would be to investigate and compare the economic cost of CRS with other 442 
similar chronic disease. 443 
Conclusion 444 
Overall, patients with CRS demonstrate a higher out-of-pocket expenditure, primary care and 445 
secondary care utilisation, and time lost from work compared to those without CRS. The study 446 
estimated an annual average OOPE of £304.84 secondary to CRS over the 3 month study 447 
period (in 2014), with a 5.3-fold greater spending on over-the-counter medication when 448 
compared to the general population. CRS is associated with an average 18.7 missed workdays 449 
per year and demonstrated an estimated incremental healthcare cost of £16.8 billion in 2014. 450 
Given that CRS is a chronic condition, and has significant prevalence and socioeconomic 451 
impact, it deserves attention from health authorities. Findings from this study will add 452 
important insights to the existing limited data in the UK and will directly inform NHS practice 453 
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Table 1: Comparison of demographic characteristics in participants with CRS and without CRS 
Participant Characteristics  CRS Without CRS 
  No. (value) No. (value) 
Age, mean (range)     58 (26-80) 41 (18-68) 
Age category (%) * 1-20 years old 12 8.6 2 5.4 
 21-40 years old 0 0.0 19 51.4 
 41-60 years old 67 48.2 11 29.7 
 61-80 years old 60 43.2 5 13.5 
Gender (%) * Male 66 52.5 16 32.7 
  Female  73 47.5 33 67.3 
CRS subgroup (%) CRSsNP 47 33.8 -  
 CRSwNP 81 58.3 -  
 AFRS 11 7.9 -  
Country of birth (%) UK 127 91.4 61 91.0 
  Other  12 8.6 6 9.0 
Ethnicity (%) White British 127 92.7 60 90.9 
  White Irish 2 5.0 0 0.0 
  White Other 7 5.1 4 6.1 
  Black/British-Caribbean 1 0.7 0 0.0 
  Asian/Asian British-Other 0 0.0 1 1.5 
  Mixed Other 0 0.0 1 1.5 
Age on leaving education (%) < 16 y 29 20.9 7 10.4 
  16 y 41 29.5 16 23.9 
  17-18 y 24 17.3 17 25.4 
  >19 y 43 30.9 20 29.9 
  Still studying 2 1.4 7 10.4 
Qualification (%) None 17 12.2 5 7.5 
  CSE 6 4.3 2 3 
  GCSE / O-Levels 25 18.0 8 11.9 
  NVQ 9 6.5 4 6.0 
  A-levels 8 5.8 12 17.9 
  School certificate 2 1.4 0 0.0 
  HND / Btec 7 5.0 8 11.9 
  Degree 40 28.8 23 34.3 
  Other  25 18.0 5 7.5 
Living arrangements (%) Alone 17 12.2 5 7.5 
  Spouse 62 44.6 22 32.8 
  Spouse & Parent 2 1.4 2 3.0 
  Spouse & Children 43 30.9 19 28.4 
  Spouse & Other 3 2.2 1 1.5 
  Parent 1 0.7 7 10.4 
  Parent & Other 0 0.0 1 1.5 
  Children 7 5.0 1 1.5 
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  Friends 2 1.4 8 11.9 
  Other  1 0.7 1 1.5 
Number of household (%) 1 16 11.5 5 7.5 
  2 65 46.8 26 38.8 
  3 32 23.0 19 28.4 
  4 15 10.8 12 17.9 
  >5 11 7.9 5 7.5 
Marital status (%) Single 11 7.9 17 25.4 
  Married / Partner 110 79.1 44 65.7 
  Separated 15 10.8 6 9.0 
  Widowed 3 2.2 0 0.0 
Employment (%) Full-time 38 27.3 31 46.3 
  Part-time 25 18.0 15 22.4 
  Self-employed 19 13.7 2 3.0  
Student 2 1.4 8 11.9 
  Other  1 0.7 0 0.0 
  Housewife/husband 4 2.9 2 3.0 
  Retired 50 36.0 9 13.4 
Annual income (%) < £ 10, 000  13 9.4 13 19.4 
  £ 10, 000 - 20,000 26 18.7 10 14.9 
  £ 20, 000 - 40, 000 44 31.7 21 31.3 
  £ 40, 000 - 60,000 16 11.5 6 9.0 
  > £ 60, 000 16 11.5 7 10.4 
  Prefer not to say 24 17.3 10 14.9 
Benefits (%) None 66 47.5 45 67.2 
  State pension 41 29.5 10 14.9 
  Child benefit 16 11.5 8 11.9 
  Other  9 6.5 0 0.0 
  Mixed 7 5.0 4 6.0 
Prescription drug coverage,  Paid 67 48.2 48 71.6 
no (%) Exempted 72 51.8 19 28.4 
Method of prescription  Individually 39 60.0 44 95.7 
payment (%) 3-monthly 6 9.2 0 0.0 
  Yearly 20 30.8 2 4.3 
Healthcare (%) Public only 128 92 61 91.0 
  Additional private cover 11 8.0 6 9.0 
Work environment (%) Outdoor 7 8.0 6 12.2 
  Indoor 80 92.0 43 87.8 
Work Type (%) Manual 27 32.9 14 29.2 
  Non-manual 55 67.1 34 70.8 





  Time suffered  1-15 years 85 61.2 -  
 16-30 years 40 28.8 -  
 31-45 years 11 7.9 -  
 >45 years 3 2.1 -  
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EQ-5D Index (mean)  0.77  0.94 
EQ-VAS Health score (mean)  72.81  89.85 
*Missing data on age and gender on 18 control participants, and missing data on age only for 
12 control participants  
 
Table 2: Average 3-monthly OOPE per patient in adults with CRS and adults without CRS (2014, in 
GBR £) 





  Mean Median IQR Mean Median IQR p 
Direct medical OOPE (£):        
 Medication & Health equipment:        
  Pain-relief 4.83 1.00 (5.00) 2.80 1.00 (2.00) 0.149 
  Cold and flu remedies 3.63 0.00 (2.00) 0.73 0.00 (0.00) 0.005 
  Nasal sprays 8.60 0.00 (12.0) 0.14 0.00 (0.00) <0.001 
  Other medication  6.11 0.00 (4.22) 1.75 0.00 (0.00) 0.003 
  CRS related - Health devices  6.64 0.00 (9.00) 0.00 0.00 (0.00) <0.001 
  Non-CRS related - Health devices  0.72 0.00 (0.00) 0.31 0.00 (0.00) 0.473 
  Total over-the-counter OOPE 30.54 17.00 (33.40) 5.74 1.00 (5.50) <0.001 
 Private and Alternative healthcare:        
  CRS - Alternative therapist  1.57 0.00 (0.00) 0.00 0.00 (0.00) 0.244 
  CRS - Private practitioner  0.00 0.00 (0.00) 0.00 0.00 (0.00) 1.00 
  Non-CRS - Alternative therapist  5.83 0.00 (0.00) 4.33 0.00 (0.00) 0.591 
  Non-CRS - Private practitioner  1.16 0.00 (0.00) 1.05 0.00 (0.00) 0.781 
 Total Direct medical OOPE 39.31 19.98 (40.37) 9.96 1.00 (3.50) <0.001 
Direct non-medical OOPE (£):        
 Transport cost:        
  CRS - Primary care visits  1.06 0.00 (1.50) 0.00 0.00 (0.00) <0.001 
  CRS - Secondary care visits 22.47 5.80 (9.74) 0.00 0.00 (0.00) <0.001 
  Non-CRS Primary care visits  1.55 0.00 (1.66) 1.04 0.00 (1.50) 0.741 
  Non-CRS - Secondary care visits 11.82 0.00 (3.63) 1.69 0.00 0.00 0.015 
 Total direct non-medical OOPE 36.90 10.45 (21.92) 2.73 0.00 (1.50) <0.001 
Total Overall OOPE 76.21 44.23 (71.18) 12.68 2.40 (7.89) <0.001 
 
Table 3: Average 3-monthly OOPE per patient comparing CRSsNP and CRSwNP group (2014, in 








 Mean Median IQR Mean Median IQR Mean Median IQR p 
Direct 
medical  
37.03 19.95 57.00 38.67 20.72 39.6 50.26 20.00 27.28 0.858 
Direct non 
medical 
27.05 11.61 18.00 44.99 11.10 29.73 20.18 8.10 23.09 0.283 
Overall 
OOPE  
64.08 44.50 66.09 83.10 45.29 76.74 70.44 30.60 26.18 0.313 
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Table 4: Healthcare utilisation and cost over 3 months in group with CRS and without CRS 





Variable Mean Median IQR Mean Median IQR p 
CRS services        
 Total Primary Care - CRS visits 1.91 1.00 2.00 0 0 0 <0.001 
 Total Primary care - CRS costs (£) 58.64 46.00 92.00 0 0 0 <0.001 
 Total Secondary Care-CRS visits 1.60 1 1 0 0 0 <0.001 
 Total Secondary Care-CRS costs (£) 308.55 83.00 83.00 0 0 0 <0.001 
Non-CRS services        
 Total Primary Care-Other visits 2.24 1 3 1.16 1 1 <0.001 
 Total Primary Care-Other costs (£) 71.49 46.00 92.00 40.84 13.70 46.00 0.016 
 Total Secondary Care-Other visits 1.01 0 1 0.40 0 0 0.042 
 Total Secondary Care-Other costs (£) 305.03 0 128 97.40 0 0 0.048 
Total         
 Total Primary Care Visits 4.14 2.00 4.00 1.16 1.00 2.00 <0.001 
 Total Primary Care Costs 130.13 92.00 115.00 40.84 13.70 46.00 <0.001 
 Total Secondary Care Visits 2.61 2.00 2.00 0.40 0.00 0 <0.001 
 Total Secondary Care Costs 613.58 166.00 512.00 97.40 0 0 <0.001 
Total cost primary and secondary care 743.72 286.00 673.00 138.85 41.70 59.70 <0.001 
 
Table 5: Workdays lost and its estimated absenteeism costs by employed adults with CRS and 
without CRS over 3-month period 
 
Table 6: Workdays lost and its estimated absenteeism costs by employed patients in CRSsNP and 
CRSwNP group 
 






  Mean (range)  Mean (range)  p  
Missed work days due to CRS  1.77(0-14)  1.45(0-16)  0.711  
Missed work days due to non-CRS reasons  0.45(0-3)  3.85(0-84)  0.098  
Total missed work days  2.23(0-14)  5.30(0-84)  0.343 
 
 
Table 7: Household productivity loss and its estimated costs by unemployed patients over 3-
month period 
 










Mean (range) Cost(£) p 
Missed work days due to CRS 1.96(0-
35) 
236.92 0 0 0.001 




328.79 0.73(0-8) 88.14 0.137 
Total missed work days 4.68(0-
84) 
566.07 0.73(0-8) 88.14 0.007 




Table 8:  Distribution of missed workdays period across the CRS subtypes over 3-month period  
 
 
Table 9: Average 3-monthly costs for CRS patients and control (2014, in Great British Pound £) 
 
 
Table 10. Total annual estimate of healthcare expenditure comparing CRS group versus Control 






No. of days unable to perform normal function 
due to CRS 
0.95(0-11) £45.47 0 0 0.006 
No. of days unable to perform normal function 
due to non-CRS reasons 
2.00(0-90) £95.72 3.68 (0-60) £176.32 0.611 
Total no. of days unable to perform normal 
function 
2.95(0-90) £141.06 3.68 (0-60) £176.32 0.825 
 0 days 1-7 days 8-14 days 15-30 days >30 days Total 
CRSsNP 15 5 2 0 0 22 
CRSwNP 39 11 2 1 0 53 
AFRS 4 1 1 0 1 7 






 Mean ±SD Media
n 
IQR Mean ±SD Media
n 
IQR p 
OOPE:          
 Direct medical 39.31 (53.93) 19.98 40.37 9.93 (25.77) 1.00 7.00 <0.001 
 Direct non-medical 36.90 (87.38) 10.45 21.92 6.53 (22.28) 0 2.90 <0.001 
 Subtotal 75.67 (101.76) 44.00 71.18 15.68 (32.42) 2.90 14.00 <0.001 
Health Care Costs:           
 Primary Care  130.15 (145.52) 92.00 115.00 40.84 (73.54) 13.70 46.00 <0.001 
 Secondary Care  613.58 (1052.71) 166.00 512.00 95.94 (597.69) 0 0 <0.001 
 Subtotal 743.73 (1083.54) 286.00 673.00 136.78 (652.03) 41.70 59.70 <0.001 
Productivity loss:          
 Absenteeism 566.07 (1554.75) 0 362.64 88.14 (202.18) 0 120.88 0.007 
 Household 
productivity loss 
141.06 (580.44) 0 0 176.32 (661.83) 0 0 0.825 
 Subtotal 391.78 (1264.73) 0 241.76 113.15 (387.52) 0 0 0.019 





Average total cost per patient 





Healthcare services 743.73 2974.92 136.78 547.12 
OOPE 75.67 304.84 15.68 62.72 





Total 1211.18 4844.88 265.61 1062.44 
Annual incremental difference: £3782.44 
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Table 11. Significant differences (p<0.001) displayed in mean scores between adults with CRS and 
without CRS for SNOT-22, EQ-5D Index and Health score.  *p=0.040, **p=0.017 compared with 
CRSsNP  









 Mean SD Mean SD Mean SD Mean SD p 
Total SNOT-22  41.00 23.065 32.46* 21.801 27.91 20.137 5.64 9.556 <0.001 
EQ-5D Index 0.706 0.224 0.797** 0.151 0.839 0.112 0.936 0.100 <0.001 
Health Score 70.47 21.322 73.83 18.980 75.36 13.764 89.85 8.900 <0.001 
 
Table 12. Univariate analysis and stepwise multiple linear regression model predicting total OOPE 
from the past 3 months 
 
Variable Significance Standardized 𝜷 
Coefficient  
R² 
Univariate analysis    
Demographic variables:    
 Age 0.278   
 Gender 0.092   
 Marital Status 0.657   
 Diagnosis 0.589   
 Time suffered 0.993   
Socioeconomic variables:    
 Household occupancy 0.002   
 Age at leaving education 0.104   
 Highest Academic Qualification 0.157   
 Employment status 0.016   
 Annual income 0.047   
 Benefits Status 0.767   
 Work environment 0.985   
 Work type 0.080   
 Prescription drug coverage 0.417   
 Additional private healthcare 0.239   
HRQOL variables:    
 SNOT-22 0.595   
 EQ-5D Index 0.911   
 EQ-VAS Health Score 0.293   
Final Stepwise multiple regression   0.097 
 Income 0.040 0.221   









Figure 2: Estimated average break down of overall healthcare costs in adults with 
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Please return the questionnaire to the Norwich Medical School, UEA, Norwich 
- for the attention of Mr Carl Philpott
UEA Office
Use only: 
Page 1 of 10Recruitment pack including background 1.4 vi, baseline 1.4, EQ-5D and SNOT-22
CONFIRMATION OF DIAGNOSIS WITH:
CT SCAN ENDOSCOPY
Please try to fill in ALL parts of the questionnaire, even if you do not have sinus 














Page 2 of 10
Assessment: Background D D / M M / Y Y Y YDate:
The Socioeconmic Cost of Chronic Rhinosinusitis (SoCCoR) Study
This questionnaire collects some background information about you and your household, including your social and economic 
circumstances. These things have been shown to have important links to health. Please read the questions carefully and tick 
the relevant boxes or provide information when requested.
A) Background & education
B) Living arrangements









What is your country of birth? UK Other
At what age did you leave full-time education? Less than 16 16 17-18 19+
Still in  full-time education
What is the highest level of qualification you have obtained?
None CSEs GCSEs/O-levels NVQs A-levels School certificate
HND/BTec Degree Other Please specify








NNumber of friends  
Please specify
NWhat is the total number of people living in your home?
How would you describe your marital status?
Single (never married)
Married/civil partnership/living with partner
Separated/Divorced
Widowed
Which of the following categories best describe your employment status? (Please tick all that apply)
Full-time paid employment
Part time paid employment
Self-employed
Student
Other (e.g. voluntary work)
Housewife/husband




N NUsing the attached sheet please enter the code of your ethnic background?















Prefer not to say
Do you or your household receive any of the following welfare benefits? (Please tick all that apply)
None State pension Child Benefit
Other
D) Health issues
Approximately how long have you suffered with chronic rhinosinusitis? years.
If you are in paid employment,
outdoors indoors
manual non-manual
what type of environment do you work in?
is your work mainly?
Please specify
12. Do you pay for your prescriptions? Yes No
If yes, how do you pay for your prescriptions? Individually 3-monthly Yearly
14. Do you have private health insurance? Yes No
...and what level of cover do you have?
If yes, how long have you had this for?







Assessment: Baseline D D / M M / Y Y Y YDate:
The Socioeconmic Cost of Chronic Rhinosinusitis (SoCCoR) Study
These questions help us to understand how your chronic rhinosinusitis (CRS) affects your use of health services and how 
much your chronic rhinosinusitis costs you and your family.  Please read the questions carefully and tick the relevant boxes or 
provide information when requested.  If you cannot remember things exactly please give your best estimate.  Feel free to add 
any of your own notes.  All responses are confidential and your data will be handled in the way described on the consent form 
you signed to take part in this study.  In particular no information that could lead to you being identified from your responses will 
be released.
A) Hospital visits
1. In the last 3 months, how many times have you been in hospital?
N NNo. of Nights:
In relations to visits for CRS:
2. When you travel to the hospital how do you normally get there?
(for costs please use your best guess if you can't remember exact amounts)
Walk or cycle
Hospital or community transport
Car
Public transport or taxi
N N NReturn distance (miles):
£ £ . p pCharge for this:
£ £ . p pParking cost:
£ £ . p pCost of return fare:
hour(s):3. Around how much time would an ordinary outpatients visit to this hospital normally take 
out of your day, including travelling, waiting and consultation time?
Do you have to take time off work to attend your hospital appointments? Yes No4.
If yes, do you: Lose pay Get full pay Get sick pay I am not in employment
Does somebody else usually accompany you to the hospital? Yes No5.
If yes, do they: Lose pay Get full pay Not work
Do you need to arrange child care or care for someone else when you go to the hospital? Yes No6.
If yes, please provide details of any cost involved:
B) Community health and social services
7. In the last 3 months, how many times have you consulted your GP?











NFor an outpatient appointment
For a daycare appointment













8. In the last 3 months, how many times have you consulted a nurse from your local surgery?
9. When you travel to your GP how do you normally get there?
(for costs please use your best guess if you can't remember exact amounts)
N N hour(s):10. Around how much time would a visit to the GP surgery normally take out of your day, 
including travelling, waiting and consultation time?
Do you have to take time off work to attend appointments at the GP surgery? Yes No11.
If yes, do you: Lose pay Get full pay Get sick pay I am not in employment
Does somebody else usually accompany you to the GP surgery? Yes No12.
If yes, do they: Lose pay Get full pay Not work
Do you need to arrange child care or care for someone else when you go to the GP surgery? Yes No13.
If yes, please provide details of any cost involved:
Walk or cycle
Hospital or community transport
Car
Public transport or taxi
N N NReturn distance (miles):
£ £ . p pCharge for this:
£ £ . p pParking cost:
£ £ . p pCost of return fare:
14. In the last 3 months, how many times have you seen a complementary therapist or alternative medicine practitioner? 
e.g. acupuncturist, homeopath, chiropractor, osteopath, reflexologist, naturopath?
C) Private and Alternative Healthcare
Type of practitioner seen (and no of times):
£ £ . p p
Amount paid
for your CRS?:






£ £ . p p
:
£ £ . p pN N
15. In the last 3 months, how many times have you paid for any private health care? e.g doctor, physiotherapist
Type of practitioner seen (and no of times):
£ £ . p p
Amount paid
for your CRS?:






£ £ . p p
:
£ £ . p pN N
















D) Medications and equipment
16. In the last 3 months, have you paid for any non-prescription ("over the counter") medicines under the following 
categories (for any reason, not just your CRS - use approximate costs):
Name of product
£ £ . p p
Total spent on product over last three months
£ £ . p p
:
£ £ . p p
:
£ £ . p p
:
Pain killers (e.g. paracetamol, aspirin)
Name of product
£ £ . p p
Total spent on product over last three months
£ £ . p p
:
£ £ . p p
:
£ £ . p p
:
Cold and 'flu remedies (e.g. 'flu powders, decongestant tablets or inhaltion remedies, cough sweets/syrups)
Name of product
£ £ . p p
Total spent on product over last three months
£ £ . p p
:
£ £ . p p
:
£ £ . p p
:
Nasal sprays (e.g. beclomethasone, sinus rinses)
Name of product
£ £ . p p
Total spent on product over last three months
£ £ . p p
:
£ £ . p p
:
£ £ . p p
:
Other (e.g. vitamins & minerals)







17. In the last 3 months have you been issued with or bought any health aids, devices or equipment you have not 
already told us about in previous questions?
e.g. sinus bottles, tissues, etc.
Or from: GP Social services Hospital
£ £ . p p
own cost
£ £ . p p
£ £ . p p
Item





Or from: GP Social services Hospital
£ £ . p p
18. How many prescriptions have you paid for:
N N.....for CRS N Nfor other diseases N N(exempt from charges)
E) Phone calls
19. In the last 3 months, around how many phone calls have you made to any health or social 
services (excluding any you have already told us about in previous questions (7 & 8)?
N N
F) Days off
20. In the last 3 months, around how many days have you been off work and/or unable to 
perform your normal activities:
N Nbecause of your CRS? (days) N Nfor other reasons? (days)
When you are unwell, does someone else usually give up time to look after you? Yes No21.
If yes, do they: Lose pay Get full pay Not work






Under each heading, please tick the ONE box that best describes your health TODAY
Mobility
I have no problems in walking about 
I have slight problems in walking about 
I have moderate problems in walking about 
I have severe problems in walking about 
I am unable to walk about
Self-Care
I have no problems washing or dressing myself 
I have slight problems washing or dressing myself 
I have moderate problems washing or dressing myself 
I have severe problems washing or dressing myself 
I am unable to wash or dress myself
USUAL ACTIVITIES (e.g. work, study, housework, 
family or leisure activities)
I have no problems doing my usual activities 
I have slight problems doing my usual activities 
I have moderate problems doing my usual activities 
I have severe problems doing my usual activities 
I am unable to do my usual activities
Pain/Discomfort
I have no pain or discomfort 
I have slight pain or discomfort 
I have moderate pain or discomfort 
I have severe pain or discomfort 
I have extreme pain or discomfort
Anxiety/Depression
I am not anxious or depressed 
I am slightly anxious or depressed 
I am moderately anxious or depressed 
I am severely anxious or depressed 
I am extremely anxious or depressed
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• We would like to know how good or bad your health is 
TODAY.
• This scale is numbered from 0 to 100.
• 100 means the best health you can imagine.
0 means the worst health you can imagine.
• Mark an X on the scale to indicate how your health is TODAY. 
• Now, please write the number you marked on the scale in the
box below.
N N NYOUR HEALTH TODAY: 









Below you will find a list of symptoms and social/emotional consequences of your nasal disorder. We would like to know more 
about these problems and would appreciate your answering the following questions to the best of your ability. There are no right 
or wrong answers and only you can provide us with this information.  Please rate your problems over the last two weeks.
Considering how severe the problem is when you experience it and how frequently it happens, please rate each item below on 
how "bad" it is by filling in the box that corresponds to how you feel. (Fill one box only per item)
Then, pick the 5 that are the most important items affecting your health and fill in the corresponding box in the grey column on 
the right.













Wake up at night























Thank you for taking part in this survey




Appendix 2.  Unit Cost used in SoCCoR economic analysis 
Resource use Unit Cost 
2014 
Source 
Primary Care Contacts   
GP consultation £ 46 Unit Costs of Health and Social Care 2014. 
General Practitioner Unit Costs (Section 
10.8b)22 
GP home visit £114 Unit Costs of Health and Social Care 2013. 
General Practitioner Unit Costs (Section 
10.8b)37 
GP telephone consultation £28 Unit Costs of Health and Social Care 2014. 
General Practitioner Unit Costs (Section 
10.8b) 22 
GP Practice nurse consultation £13.70 Unit Costs of Health and Social Care 2014. 
Derived from Nurse - GP Practice (Section 
10.6) 22 
GP Practice nurse home visit £22.03 Unit Costs of Health and Social Care 2014. 
Derived from Nurse - GP Practice (Section 
10.6) 22 
GP Practice nurse telephone 
consultation 
£4.10 Unit Costs of Health and Social Care 2014. 
Derived from Nurse - GP Practice (Section 
10.6) 22 
Secondary Care Contacts   
ENT outpatient attendance £83 NHS Reference Costs 2013/2014. WF01A 
Consultant led follow-up attendance (ENT)23 
Outpatient attendance £128 NHS Reference Costs 2013/2014. Outpatient - 
Consultant led23 
Day hospital visit (CRS-related) £1533 NHS Reference Costs 2013/14. Weighted 
average across sinus related day case 
attendances CA26Z- CA29Z 23 
Day hospital visit (Non-specific) £698 NHS Reference Costs 2013/14. Weighted 
average across all day case attendances23 
Inpatient attendance (ENT ward) £346 NHS Reference Costs 2013/14. Weighted 
average across sinus related elective and non-
elective excess bed days CA26Z- CA29Z23 
Inpatient attendance (Non-specific) £301 NHS Reference Costs 2013/14. Weighted 




Appendix 3. Assumptions and Calculation  
Cost of productivity loss were derived from assumptions of relevant literature outlined below: 
 
Reference parameters  
Parameter Baseline values Source 
Population 16-24 (2014) 40,389,000 ONS (2014a)38 
Employment rate ( April 2014) 72.9% ONS (2014a)38 
Number of working adults in employment (2014) 30,535,000  ONS (2014a)38 
Hourly rate (£mean) £15.11 ONS (2014b)39  
Average hours worked per year (2014) 1531 OECD (2014) 40  
UK Population in 2030 71,400,000 ONS (2011)41 
Weekly earnings for caring, leisure and other service 
occupations (median) 
£335 per week ONS (2014b)42  






Average daily wage  
 
£ 120.88 = Hourly rate (£mean) * 8  
(Eight hour working day assumed) 
Average days worked per year 191.37 = Average hours worked per year / 8 (Eight 
hour working day assumed) 
Daily earning for caring, leisure and 
other service occupation (median) 
£47.86 =Weekly rate / 7 (seven working day assumed)  
 
Calculation of CRS cost 
Parameter Assumptions Source / Calculation  
CRS prevalence 11% Hastan, et al. (2011)1 
Working age population with 
CRS in 2014 
3,358,850 CRS prevalence x Number of working adults 
in employment (2014) 
Cost of workdays missed due to 
CRS per year per CRS individual 
£236.92 x 4  
=£947.68  
Cost of workdays missed due to CRS per 3 
monthly x 4   
Cost of workdays missed due to 




Cost of workdays missed due to CRS per 
year x Number of working CRS adults 
Overall healthcare cost of CRS 
for 2014 




CRS prevalence x Population x Estimated 
annual average cost of CRS 
Overall incremental cost of CRS 
for 2014 




CRS prevalence x Population x Estimated 
annual average incremental cost of CRS 
 
  
 
